Search Results - "Durez, Patrick"

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database by Taylor, Peter C, Takeuchi, Tsutomu, Burmester, Gerd R, Durez, Patrick, Smolen, Josef S, Deberdt, Walter, Issa, Maher, Terres, Jorge Ross, Bello, Natalia, Winthrop, Kevin L

“…To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid…”
Get more information

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial by Rivellese, Felice, Surace, Anna E. A., Goldmann, Katriona, Sciacca, Elisabetta, Çubuk, Cankut, Giorli, Giovanni, John, Christopher R., Nerviani, Alessandra, Fossati-Jimack, Liliane, Thorborn, Georgina, Ahmed, Manzoor, Prediletto, Edoardo, Church, Sarah E., Hudson, Briana M., Warren, Sarah E., McKeigue, Paul M., Humby, Frances, Bombardieri, Michele, Barnes, Michael R., Lewis, Myles J., Pitzalis, Costantino

“…Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased…”
Get full text

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force by Smolen, Josef S, Breedveld, Ferdinand C, Burmester, Gerd R, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K, Navarro-Compán, M Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Betteridge, Neil, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J, Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G, van Vollenhoven, Ronald, de Wit, Martinus, van der Heijde, Desirée

“…Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The…”
Get more information

Should we stop methotrexate or not for vaccination? by Durez, Patrick, Combe, Bernard

“…The rationale is simple and refer to the association of dose response of antibody titres after vaccination and protection against symptomatic SARS-CoV-2…”
Get full text

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial by Smolen, Josef S, Prof, Nash, Peter, MD, Durez, Patrick, Prof, Hall, Stephen, MD, Ilivanova, Elena, MD, Irazoque-Palazuelos, Fedra, MD, Miranda, Pedro, MD, Park, Min-Chan, MD, Pavelka, Karel, Prof, Pedersen, Ronald, MS, Szumski, Annette, MS, Hammond, Constance, BS, Koenig, Andrew S, DO, Vlahos, Bonnie, BSN

“…Summary Background Clinical remission and low disease activity are essential treatment targets in patients with rheumatoid arthritis. Although moderately…”
Get full text

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial by Smolen, Josef S, Prof, Emery, Paul, Prof, Fleischmann, Roy, Prof, van Vollenhoven, Ronald F, Prof, Pavelka, Karel, Prof, Durez, Patrick, Prof, Guérette, Benoît, PhD, Kupper, Hartmut, MD, Redden, Laura, MD, Arora, Vipin, PhD, Kavanaugh, Arthur, Prof

“…Summary Background Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological…”
Get full text

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review by Emery, Paul, Durez, Patrick, Hueber, Axel J, de la Torre, Inmaculada, Larsson, Esbjörn, Holzkämper, Thorsten, Tanaka, Yoshiya

“…Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid…”
Get full text

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial by Emery, Paul, Prof, Breedveld, Ferdinand C, Prof, Hall, Stephen, MD, Durez, Patrick, MD, Chang, David J, MD, Robertson, Deborah, MS, Singh, Amitabh, PhD, Pedersen, Ronald D, MS, Koenig, Andrew S, DO, Freundlich, Bruce, MD

“…Summary Background Remission and radiographic non-progression are goals in the treatment of early rheumatoid arthritis. The aim of the combination of…”
Get full text

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis by Hueber, Wolfgang, Patel, Dhavalkumar D, Dryja, Thaddeus, Wright, Andrew M, Koroleva, Irina, Bruin, Gerard, Antoni, Christian, Draelos, Zoe, Gold, Michael H, Durez, Patrick, Tak, Paul P, Gomez-Reino, Juan J, Foster, C Stephen, Kim, Rosa Y, Samson, C Michael, Falk, Naomi S, Chu, David S, Callanan, David, Nguyen, Quan Dong, Rose, Kristine, Haider, Asifa, Di Padova, Franco

“…Interleukin-17A (IL-17A) is elaborated by the T helper 17 (T(H)17) subset of T(H) cells and exhibits potent proinflammatory properties in animal models of…”
Get more information

Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort by Natalucci, Francesco, Triaille, Clément, Van Mullem, Cécile, Sokolova, Tatiana, Sapart, Emilie, de Bellefon, Laurent Meric, Nzeusseu, Adrien, Galant, Christine, Lauwerys, Bernard, Durez, Patrick

“…Rheumatoid Arthritis (RA) often exhibits suboptimal treatment response despite early diagnosis and treatment. This study aimed to analyze Early Rheumatoid…”
Get full text

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study by Fleischmann, Roy, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles G, Durez, Patrick, Tanaka, Yoshiya, Swierkot, Jerzy, Khan, Nasser, Bu, Xianwei, Li, Yihan, Song, In-Ho

“…ObjectivesTo assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in the ongoing long-term…”
Get full text

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study by Alten, Rieke, Gomez-Reino, Juan, Durez, Patrick, Beaulieu, Andre, Sebba, Anthony, Krammer, Gerhard, Preiss, Ralph, Arulmani, Udayasankar, Widmer, Albert, Gitton, Xavier, Kellner, Herbert

“…Background Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA). This…”
Get full text

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials by Combe, Bernard, Allanore, Yannick, Alten, Rieke, Caporali, Roberto, Durez, Patrick, Iannone, Florenzo, Nurmohamed, Michael T, Toumi, Mondher, Lee, Sang Joon, Kwon, Taek Sang, Noh, Jiwon, Park, Gahee, Yoo, Dae Hyun

“…A subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It…”
Get full text

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment by Schiff, Michael, Takeuchi, Tsutomu, Fleischmann, Roy, Gaich, Carol L, DeLozier, Amy M, Schlichting, Douglas, Kuo, Wen-Ling, Won, Ji-Eon, Carmack, Tara, Rooney, Terence, Durez, Patrick, Shaikh, Saeed, Hidalgo, Rodolfo Pardo, van Vollenhoven, Ronald, Zerbini, Cristiano A F

“…This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in…”
Get full text

Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort by Dierckx, Stéphanie, Sokolova, Tatiana, Lauwerys, Bernard R, Avramovska, Aleksandra, de Bellefon, Laurent Meric, Toukap, Adrien Nzeusseu, Stoenoiu, Maria, Houssiau, Frédéric A, Durez, Patrick

“…Studies have demonstrated that rheumatoid arthritis (RA) patients who achieve low disease activity or remission are able to taper biological disease-modifying…”
Get full text

Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium by Ducreux, Julie, Durez, Patrick, Galant, Christine, Nzeusseu Toukap, Adrien, den Eynde, Benoît, Houssiau, Frédéric A., Lauwerys, Bernard R.

“…Objective To investigate the global molecular effects of tocilizumab (TCZ) in comparison with methotrexate (MTX) treatment in synovial biopsy tissue obtained…”
Get full text

The anti‐CD20 antibody rituximab reduces the Th17 cell response by van de Veerdonk, Frank L., Lauwerys, Bernard, Marijnissen, Renoud J., Timmermans, Kim, Di Padova, Franco, Koenders, Marije I., Gutierrez‐Roelens, Ilse, Durez, Patrick, Netea, Mihai G., van der Meer, Jos W. M., van den Berg, Wim B., Joosten, Leo A. B.

“…Objective Rituximab has been shown to be successful in the treatment of rheumatoid arthritis (RA), and this unexpected finding indicates that B cells have an…”
Get full text

Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial by Durez, Patrick, Vandepapeliere, Pierre, Miranda, Pedro, Toncheva, Antoaneta, Berman, Alberto, Kehler, Tatjana, Mociran, Eugenia, Fautrel, Bruno, Mariette, Xavier, Dhellin, Olivier, Fanget, Bernard, Ouary, Stephane, Grouard-Vogel, Géraldine, Boissier, Marie-Christophe

“…Active immunization, or vaccination, with tumor necrosis factor (TNF)-Kinoid (TNF-K) is a novel approach to induce polyclonal anti-TNF antibodies in…”
Get full text

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue by Triaille, Clement, Durez, Patrick, Sokolova, Tatiana, Tilman, Gaëlle, Méric de Bellefon, Laurent, Galant, Christine, Coulie, Pierre, Lauwerys, Bernard R, Limaye, Nisha

“…Our goal was to assess for the histological and transcriptomic effects of abatacept on RA synovia, and to compare them with previously published data from four…”
Get full text

Paired Rheumatoid Arthritis Synovial Biopsies From Small and Large Joints Show Similar Global Transcriptomic Patterns With Enrichment of Private Specificity TCRB and TCR Signaling Pathways by Triaille, Clement, Vansteenkiste, Louise, Constant, Manuel, Ambroise, Jérôme, Méric de Bellefon, Laurent, Nzeusseu Toukap, Adrien, Sokolova, Tatiana, Galant, Christine, Coulie, Pierre, Carrasco, Javier, Durez, Patrick, Lauwerys, Bernard R

“…We explored histological and transcriptomic profiles of paired synovial biopsies from rheumatoid arthritis (RA) patients, in order to assess homogeneity in…”
Get full text